Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.37 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8296822 | 0.90 | MAPT (0.43) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2094210 | 0.73 | ALDH1A1 (0.51) | MAPTRAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL1827846 | 0.73 | PTGS1 (0.40) | MAPTRAB9AALDH1A1MAPK1AKR1C3 | |
| SCHEMBL27915252 | 0.69 | AKR1C3 (0.52) | ALDH1A1MAPK1KIF11AKR1C3AKR1C2 | |
| SCHEMBL15858592 | 0.67 | AKR1C3 (0.47) | MAPTALDH1A1KIF11AKR1C3AKR1C2 | |
| SCHEMBL28283181 | 0.66 | AKR1C3 (0.63) | ALDH1A1AKR1C3AKR1C2ABCC8KCNJ11 | |
| SCHEMBL28020019 | 0.66 | AKR1C3 (0.46) | ALDH1A1MAPK1KIF11AKR1C3AKR1C2 | |
| SCHEMBL1852148 | 0.66 | MAPT (0.54) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 | |
| Trifluoromethylbenzene SCHEMBL29273876 | 0.66 | KIF11 (0.55) | MAPTALDH1A1MAPK1L3MBTL1KMT2A | |
| SCHEMBL16363139 | 0.66 | MAPT (0.46) | MAPTRAB9AALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524756-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-06 | — | — | US | disclosed |
| CN-102793692-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP | 2012-11-28 | — | — | CN | disclosed |
| US-8314134-B2 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112093-A2 | BENZIMIDAZOLYL-PYRIDINE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1809294-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2007-07-25 | — | — | EP | disclosed |
| CN-1826121-A | Method for regulating and controlling calcium ion release to activate calcium ion channel | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | disclosed |
| CN-1826120-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | disclosed |
| WO-2006034402-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICAL CORP. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254912-A1 | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | NLRP3, CXCR1, CXCR2 | MAPT 1930/4885RAB9A 642/4885ALDH1A1 2568/4885 |
| US-20140107134-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | MAPT 1416/4885RAB9A 1725/4885ALDH1A1 1952/4885 |
| US-20070249661-A1 | Compounds for inflammation and immune-related uses | CXCR2, CXCL8, CCR9 | MAPT 1416/4885RAB9A 1725/4885ALDH1A1 1952/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | MAPT 1416/4885RAB9A 1725/4885ALDH1A1 1952/4885 |
| US-20130142831-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | MAPT 1416/4885RAB9A 1725/4885ALDH1A1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.